Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV article

Emerging Microbes and Infections

Volumn 7, Issue 1, 2018, Pages

  Jiang, Yuting ^a   Zhao, Guangyu ^a   Song, Nianping ^a   Li, Pei ^a   Chen, Yuehong ^a   Guo, Yan ^a   Li, Junfeng ^a   Du, Lanying ^b   Jiang, Shibo ^b,c   Guo, Renfeng ^d   Sun, Shihui ^a   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

^d InflaRx GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CASPASE 3; CD68 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLINE; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE CHEMOATTRACTANT; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RESPIRATORY TRACT AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS RNA; C5AR1 PROTEIN, MOUSE; CHEMOKINE; COMPLEMENT INHIBITOR; DPP4 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL REGENERATION; CLINICAL OBSERVATION; CLINICAL OUTCOME; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LUNG INJURY; LUNG PARENCHYMA; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SHAM PROCEDURE; SPLEEN CELL; SPLEEN INJURY; SPLEEN TISSUE; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CORONAVIRUS INFECTION; CYTOLOGY; DISEASE MODEL; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; LUNG; PATHOGENICITY; PATHOLOGY; SPLEEN; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; APOPTOSIS; CHEMOKINES; COMPLEMENT ACTIVATION; COMPLEMENT C5A; COMPLEMENT INACTIVATING AGENTS; CORONAVIRUS INFECTIONS; CYTOKINES; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; LUNG; MICE; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR, ANAPHYLATOXIN C5A; SPLEEN; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 85045878614     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/s41426-018-0063-8     Document Type: Article

References (45)

1. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820 (2012).
2. Hui, D. S., Memish, Z. A. & Zumla, A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr. Opin. Pulm. Med. 20, 233-241 (2014).
3. Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752-761 (2013).
4. Al-Abdallat, M. M. et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 59, 1225-1233 (2014).
5. Memish, Z. A. et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr. Infect. Dis. J. 33, 904-906 (2014).
6. Arabi, Y. M. et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann. Intern. Med. 160, 389-397 (2014).
7. Lau, Y. L. & Peiris, J. S. Pathogenesis of severe acute respiratory syndrome. Curr. Opin. Immunol. 17, 404-410 (2005).
8. Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4, e00165-00113 (2013).
9. Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS ONE 9, e88716 (2014).
10. Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331-1342 (2014).
11. van den Brand, J. M., Smits, S. L. & Haagmans, B. L. Pathogenesis of Middle East respiratory syndrome coronavirus. J. Pathol. 235, 175-184 (2015).
12. Vijay, R. & Perlman, S. Middle East respiratory syndrome and severe acute respiratory syndrome. Curr. Opin. Virol. 16, 70-76 (2016).
13. Huang, K. J. et al. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 75, 185-194 (2005).
14. Cameron, M. J. et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81, 8692-8706 (2007).
15. Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136, 95-103 (2004).
16. Lau, S. K. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J. Gen. Virol. 94(Part 2), 2679-2690 (2013).
17. Baskin, C. R. et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl. Acad. Sci. USA 106, 3455-3460 (2009).
18. Wong, G. W., Li, A. M., Ng, P. C. & Fok, T. F. Severe acute respiratory syndrome in children. Pediatr. Pulmonol. 36, 261-266 (2003).
19. Cao, B. & Hayden, F. G. Therapy of H7N9 pneumonia: current perspectives. Expert. Rev. Anti. Infect. Ther. 11, 1123-1126 (2013).
20. Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831-3838 (2013).
21. Hawlisch, H. et al. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22, 415-426 (2005).
22. Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46, 2753-2766 (2009).
23. Schindler, R., Gelfand Ja Fau-Dinarello, C. A. & Dinarello, C. A. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76, 1631-1638 (1990).
24. Patel, S. N. et al. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J. Exp. Med. 205, 1133-1143 (2008).
25. Sun, S. et al. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am. J. Respir. Cell. Mol. Biol. 49, 221-230 (2013).
26. Sun, S. et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin. Infect. Dis. 60, 586-595 (2015).
27. Zhao, G. et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with middle east respiratory syndrome-coronavirus. PLoS ONE 10, e0145561 (2015).
28. Sun, S. et al. Complement inhibition alleviates paraquat-induced acute lung injury. Am. J. Respir. Cell. Mol. Biol. 45, 834-842 (2011).
29. Boonacker, E. & Van Noorden, C. J. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell. Biol. 82, 53-73 (2003).
30. Agrawal, A. S. et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659-3670 (2015).
31. Bokisch, V. A., Top, F. H. Jr, Russell, P. K., Dixon, F. J. &Muller-Eberhard, H. J. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N. Engl. J. Med. 289, 996-1000 (1973).
32. Bokisch, V. A., Muller-Eberhard, H. J. & Dixon, F. J. The role of complement in hemorrhagic shock syndrome (dengue). Trans. Assoc. Am. Physicians 86, 102-110 (1973).
33. Churdboonchart, V., Bhamarapravati, N. & Futrakul, P. Crossed immunoelectrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. Observations in patients' plasma. Am. J. Trop. Med. Hyg. 32, 569-576 (1983).
34. Avirutnan, P. et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193, 1078-1088 (2006).
35. Ubol, S. et al. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J. Infect. Dis. 197, 1459-1467 (2008).
36. Morrison, T. E., Fraser, R. J., Smith, P. N., Mahalingam, S. & Heise, M. T. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J. Virol. 81, 5132-5143 (2007).
37. Chan, J. F. et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207, 1743-1752 (2013).
38. Chu, H. et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 454-455, 197-205 (2014).
39. Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat. Rev. Immunol. 5, 606-616 (2005).
40. den Haan, J. M. & Kraal, G. Innate immune functions of macrophage subpopulations in the spleen. J. Innate Immun. 4, 437-445 (2012).
41. Kurotaki, D. et al. CSF-1-dependent red pulp macrophages regulate CD4 T cell responses. J. Immunol. 186, 2229-2237 (2011).
42. Fang, C., Miwa, T., Shen, H. & Song, W. C. Complement-dependent enhancement of CD8+T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J. Immunol. 179, 3178-3186 (2007).
43. Grailer, J. J., Fattahi, F., Dick, R. S., Zetoune, F. S. & Ward, P. A. Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice. J. Immunol. 194, 868-872 (2015).
44. Ward, P. A. The harmful role of c5a on innate immunity in sepsis. J. Innate Immun. 2, 439-445 (2010).
45. Chu, H. et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J. Infect. Dis. 213, 904-914 (2016).